Monthly
US$200
Billed every month
Vancomycin Hydrochloride for Injection(注射用盐酸万古霉素)
Companies, stages and changes, with each record available on this page.
Last 90 days: No longer listed under review: 1 application
Current coverage may be incomplete
Which companies are listed, and at what stages?
Each source is counted separately. Expand a list to inspect companies, identifiers, dates and sources.
Company names, approval identifiers and strengths are retained as recorded in the Chinese sources. Category labels include the original wording for verification.
Catalogue holders12View records ↓
Under-review filings4View records ↓
This year’s generic filers4View records ↓
NHSA approval numbers15View records ↓
API companies with A status6View records ↓
Chemical-drug catalogue
Loaded records: 12 holders; 3 in the quality-and-efficacy consistency-evaluation category, and 8 in the new chemical-registration-classification generic category. Category counts may overlap.
| Marketing authorization holder | Manufacturer | Approval number | Approved | Strength / specification | Catalogue category (source text) | View source |
|---|---|---|---|---|---|---|
| 福安药业集团湖北人民制药有限公司 | 福安药业集团湖北人民制药有限公司 | 国药准字H20265043 | 2026/06/30 | 0.5g（50万单位）（按C66H75Cl2N9O24计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 安徽省先锋制药有限公司 | 安徽省先锋制药有限公司 | 国药准字H20264232 | 2026/05/07 | 0.5g（50万单位）（按C66H75Cl2N9O24计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 华北制药股份有限公司 | 华北制药股份有限公司 | 国药准字H20255230 | 2025/08/26 | 0.5g（50万单位）（按C66H75Cl2N9O24计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 海南倍特药业有限公司 | 海南倍特药业有限公司 | 国药准字H20253781 | 2025/04/01 | 0.5g（50万单位）（按C66H75Cl2N9O24计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 山东鲁抗医药股份有限公司 | 成都通德药业有限公司 | 国药准字H20244955 | 2024/09/19 | 0.5g（50万单位）（按C66H75Cl2N9O24计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 南京恒道医药科技股份有限公司 | 江苏九旭药业有限公司 | 国药准字H20244808 | 2024/09/03 | 0.5g(50万单位)(按C66H75Cl2N9O24计) | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 海南普利制药股份有限公司 | 海南普利制药股份有限公司 | 国药准字H20243660 | 2024/05/08 | 0.5g（50万单位）（按C66H75Cl2N9O24计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 丽珠集团丽珠制药厂 | 丽珠集团丽珠制药厂 | 国药准字H20193378 | 2023/04/05 | 0.5g（50万单位）（按C66H75Cl2N9O24计） | Drug that passed quality-and-efficacy consistency evaluation (通过质量和疗效一致性评价的药品) | CDE |
| 浙江海正药业股份有限公司 | 浙江海正药业股份有限公司 | 国药准字H20084268 | 2021/11/15 | 0.5g（50万单位）（按C66H75Cl2N9O24计） | Drug that passed quality-and-efficacy consistency evaluation (通过质量和疗效一致性评价的药品) | CDE |
| 浙江医药股份有限公司 | 浙江医药股份有限公司新昌制药厂 | 国药准字H20033366 | 2021/06/03 | 0.5g（50万单位）（按C66H75Cl2N9O24计） | Drug that passed quality-and-efficacy consistency evaluation (通过质量和疗效一致性评价的药品) | CDE |
| VANCOCIN ITALIA S.R.L. | VIANEX S.A.(PLANT C) | H20140174 | 1988/10/15 | 500mg | Imported originator drug (进口原研药品) | CDE |
| 重庆药友制药有限责任公司 | 重庆药友制药有限责任公司 | 国药准字H20254904 | 2025/07/22 | 0.5g（50万单位）（按C66H75Cl2N9O24计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
NHSA drug codes
Loaded records: 15 distinct approval numbers and 14 companies.
| Company / applicant | Approval number | Strength / specification | NHSA class | NHSA drug code | View source |
|---|---|---|---|---|---|
| 丽珠集团丽珠制药厂 | 国药准字H20193378 | 0.5g(50万单位)(按C₆₆H₇₅Cl₂N₉O₂₄计) | Category B (乙) | XJ01XAW001B001010100453 | NHSA |
| 重庆药友制药有限责任公司 | 国药准字H20254904 | 0.5g(50万单位)(按C₆₆H₇₅Cl₂N₉O₂₄计) | Category B (乙) | XJ01XAW001B001010101066 | NHSA |
| 华北制药股份有限公司 | 国药准字H20255230 | 0.5g(50万单位)(按C₆₆H₇₅Cl₂N₉O₂₄计) | Category B (乙) | XJ01XAW001B001010102690 | NHSA |
| 安徽省先锋制药有限公司 | 国药准字H20264232 | 0.5g(50万单位)(按C₆₆H₇₅Cl₂N₉O₂₄计) | Category B (乙) | XJ01XAW001B001010104339 | NHSA |
| 浙江海正药业股份有限公司 | 国药准字H20084268 | 0.5g(50万单位)(按C66H75Cl2N9O24计) | Category B (乙) | XJ01XAW001B001010104641 | NHSA |
| 浙江医药股份有限公司新昌制药厂 | 国药准字H20033366 | 0.5g(50万单位)(按C₆₆H₇₅Cl₂N₉O₂₄计) | Category B (乙) | XJ01XAW001B001010104747 | NHSA |
| 海南倍特药业有限公司 | 国药准字H20253781 | 0.5g(50万单位)(按C66H75Cl2N9O24计) | Category B (乙) | XJ01XAW001B001010105791 | NHSA |
| 海南普利制药股份有限公司 | 国药准字H20243660 | 0.5g(50万单位)(按C₆₆H₇₅Cl₂N₉O₂₄计) | Category B (乙) | XJ01XAW001B001010105801 | NHSA |
| 福安药业集团湖北人民制药有限公司 | 国药准字H20265043 | 0.5g(50万单位)(按C₆₆H₇₅Cl₂N₉O₂₄计) | Category B (乙) | XJ01XAW001B001010109554 | NHSA |
| VANCOCIN ITALIA S.R.L. | 国药准字HJ20140174 | 0.5g(50万单位)(按C₆₆H₇₅Cl₂N₉O₂₄计) | Category B (乙) | XJ01XAW001B001010178400 | NHSA |
| CJ HealthCare Corporation | H20171132 | 0.5g(相当于万古霉素50万单位) | Category B (乙) | XJ01XAW001B001010179134 | NHSA |
| Gentle pharma Co.,Ltd. | HC20150054 | 0.5g(按万古霉素计) | Category B (乙) | XJ01XAW001B001010179360 | NHSA |
| 南京恒道医药科技股份有限公司 | 国药准字H20244808 | 0.5g(50万单位)(按C₆₆H₇₅Cl₂N₉O₂₄计) | Category B (乙) | XJ01XAW001B001010183035 | NHSA |
| 山东鲁抗医药股份有限公司 | 国药准字H20244955 | 0.5g(50万单位)(按C₆₆H₇₅Cl₂N₉O₂₄计) | Category B (乙) | XJ01XAW001B001010183198 | NHSA |
| 丽珠集团丽珠制药厂 | 国药准字H20193378 | 0.5g(50万单位)(按C₆₆H₇₅Cl₂N₉O₂₄计) | Category B (乙) | XJ01XAW001B001010200453 | NHSA |
| 安徽省先锋制药有限公司 | 国药准字H20264232 | 0.5g(50万单位)(按C₆₆H₇₅Cl₂N₉O₂₄计) | Category B (乙) | XJ01XAW001B001010204339 | NHSA |
| 浙江海正药业股份有限公司 | 国药准字H20084268 | 0.5g(50万单位)(按C66H75Cl2N9O24计) | Category B (乙) | XJ01XAW001B001010204641 | NHSA |
| 海南倍特药业有限公司 | 国药准字H20253781 | 0.5g(50万单位)(按C66H75Cl2N9O24计) | Category B (乙) | XJ01XAW001B001010205791 | NHSA |
| 海南普利制药股份有限公司 | 国药准字H20243660 | 0.5g(50万单位)(按C₆₆H₇₅Cl₂N₉O₂₄计) | Category B (乙) | XJ01XAW001B001010205801 | NHSA |
| 福安药业集团湖北人民制药有限公司 | 国药准字H20265043 | 0.5g(50万单位)(按C₆₆H₇₅Cl₂N₉O₂₄计) | Category B (乙) | XJ01XAW001B001010209554 | NHSA |
| Gentle pharma Co.,Ltd. | HC20150054 | 0.5g(按万古霉素计) | Category B (乙) | XJ01XAW001B001010279360 | NHSA |
| 南京恒道医药科技股份有限公司 | 国药准字H20244808 | 0.5g(50万单位)(按C₆₆H₇₅Cl₂N₉O₂₄计) | Category B (乙) | XJ01XAW001B001010283035 | NHSA |
| 南京恒道医药科技股份有限公司 | 国药准字H20244808 | 0.5g(50万单位)(按C₆₆H₇₅Cl₂N₉O₂₄计) | Category B (乙) | XJ01XAW001B001010383035 | NHSA |
| 浙江海正药业股份有限公司 | 国药准字H20084269 | 按C66H75Cl2N9O24计1.0g(100万单位) | Category B (乙) | XJ01XAW001B001020104641 | NHSA |
| 浙江海正药业股份有限公司 | 国药准字H20084269 | 按C66H75Cl2N9O24计1.0g(100万单位) | Category B (乙) | XJ01XAW001B001020204641 | NHSA |
Approval numbers and companies are deduplicated separately; packaging records remain individually listed. An empty insurance class means it is unstated. NHSA codes supply no approval date and do not establish the outcome of an acceptance number.
Current under-review applications
Loaded records: 4 filings and 4 distinct first applicants.
Generic 4
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| 南京海纳制药有限公司 | CYHS2600957 | Generic | 2026/04/24 | Not stated by source | CDE |
| 亿腾医药（珠海）有限公司;南京健友生化制药股份有限公司 | CYHS2600726 | Generic | 2026/03/26 | Not stated by source | CDE |
| 深圳立健药业有限公司 | CYHS2601766 | Generic | 2026/07/23 | Not stated by source | CDE |
| 石家庄四药有限公司 | CYHS2600636 | Generic | 2026/03/10 | Not stated by source | CDE |
New generic filings in 2026
Loaded records: 4 filings and 4 distinct first applicants.
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| 南京海纳制药有限公司 | CYHS2600957 | Generic | 2026/04/24 | Not stated by source | CDE |
| 亿腾医药（珠海）有限公司;南京健友生化制药股份有限公司 | CYHS2600726 | Generic | 2026/03/26 | Not stated by source | CDE |
| 深圳立健药业有限公司 | CYHS2601766 | Generic | 2026/07/23 | Not stated by source | CDE |
| 石家庄四药有限公司 | CYHS2600636 | Generic | 2026/03/10 | Not stated by source | CDE |
API registrations
Non-component matches: 6 companies with A status and 5 I-status records. Component matches are listed separately and excluded from these counts.
| Name | Company / applicant | Registration number | Status | Name match | Source update date | View source |
|---|---|---|---|---|---|---|
| 万古霉素 | 雅赛利（台州）制药有限公司 | Y20260000210 | I | Salt-normalized ingredient | 2026/04/20 | CDE |
| 盐酸万古霉素 | 浙江昌海制药有限公司 | Y20240000397 | I | Exact ingredient | 2024/04/22 | CDE |
| 盐酸万古霉素 | 北大医药重庆大新药业股份有限公司 | Y20230000840 | I | Exact ingredient | 2023/10/19 | CDE |
| 盐酸万古霉素 | 浙江昌海制药有限公司 | Y20230000281 | A | Exact ingredient | 2025/03/06 | CDE |
| 盐酸万古霉素 | 北大医药重庆大新药业股份有限公司 | Y20210000777 | I | Exact ingredient | 2024/11/12 | CDE |
| 盐酸万古霉素 | 核芯医药（山东）有限公司 | Y20190000434 | I | Exact ingredient | 2020/06/03 | CDE |
| 盐酸万古霉素 | 浙江医药股份有限公司新昌制药厂 | Y20190009487 | A | Exact ingredient | — | CDE |
| 盐酸万古霉素 | 华北制药华胜有限公司 | Y20190006976 | A | Exact ingredient | — | CDE |
| 盐酸万古霉素 | 浙江海正药业股份有限公司 | Y20190006263 | A | Exact ingredient | 2025/07/04 | CDE |
| 盐酸万古霉素 | 浙江医药股份有限公司新昌制药厂 | Y20180001287 | A | Exact ingredient | 2025/03/18 | CDE |
| 盐酸万古霉素 | 丽珠集团福州福兴医药有限公司 | Y20170000276 | A | Exact ingredient | 2026/09/03 | CDE |
| 盐酸万古霉素 | 雅赛利(台州)制药有限公司 | Y20170000173 | A | Exact ingredient | 2024/10/22 | CDE |
A/I are source statuses. Matching uses exact ingredients, salt-normalized names and maintained combination components, without fuzzy matching. A-status companies are deduplicated by the first registered company. Components are excluded from headline counts; the register does not identify the associated formulation.
What changed recently?
Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately.
Trial registration does not mean an application will follow.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
NHSA edition maintained to 2026-10-23; latest successful catalogue check: 2026/11/10 07:23. NHSA records lack approval dates; only an earlier edition or observation establishes precedence.
-
2026/11/06No longer listed under review
湖北美林药业有限公司
CYHS2501535
Fact date: 2026/11/06 · Site observation date: 2026/11/06
Accepted: 2025/04/23
not on the CDE under-review list in this snapshot; the review / approval outcome is to be checked
View source ↗
How current is each source?
- CDE acceptances and review
- Last successful update: 2026/11/10 07:27
- Chemical-drug catalogue
- Last successful update: 2026/11/10 07:23
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
- Full API register
- Last successful update: 2026/11/10 07:25
- NHSA drug codes
- Last successful update: 2026/11/05 06:45
The fully loaded edition was maintained to 2026-10-23. Publication lags maintenance: the verified 2026-10-16 edition was published on 10-28, a 12-day gap. This is not a fixed lag for every edition.
- NMPA drug delivery notices
- Last successful update: 2026/11/10 18:31
First index-page publication dates: 2026-10-26 to 2026-11-10; 0 pages pending. Covers loaded notices only, not a complete historical approval database.
- Drug Clinical Trial Registry and Information Disclosure Platform
- Last successful update: 2026/11/10 08:10 · Current coverage may be incomplete
Daily collection reads new registrations. Backfill covers registration numbers from 2025 onward (CTR2025/CTR2026), not first-publication years. States are dated observations; revisions are not tracked.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
Public-product searches scanned: 3/30; discovered pending details: 20. Record counts in unscanned portions remain unknown.
Filings are counted by acceptance number and filing companies by first applicant. Strengths may have separate applications. Drug names are normalized only for width and whitespace; distinct generic names, dosage forms and combinations remain separate. Unstated strengths are marked. Company counts from different sources must not be added together.
Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.
Free follow
Follow changes to Vancomycin Hydrochloride for Injection
Up to 3 drugs per email address, in one weekly digest. Starts after email confirmation; unsubscribe at any time.
Subscriptions
Next-day facts and deliverable timelines
- One email the next day when new facts are collected for your followed products.
- Export the complete loaded event timeline for each followed product as CSV.
- Add up to 4 additional recipients, each confirmed by email.
- Increase your follow limit from 3 to 10 products.
Quarterly
US$540
Billed every three months
US$180 per month
Yearly
US$1,920
Billed every year
US$160 per month
Online subscriptions are not enabled. The form below registers interest; it does not charge or activate access.
Separate one-time purchase
US Orange Book × China records comparison
Full table and CSV export for 12 months from payment, with monthly data updates. No automatic renewal.
Subscriptions and comparison-table access are purchased separately. Neither includes the other.
US$490
One payment · 12 months of access
Online comparison-table purchase is not enabled.
Billed by Creem, our merchant of record · Terms · Refund policy